<DOC>
	<DOCNO>NCT00025571</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make tumor cell sensitive light kill tumor cell . Photosensitizing drug HPPH absorb tumor cell , expose light , become active kill tumor cell . PURPOSE : Phase I trial study effectiveness photodynamic therapy HPPH treat patient non-small cell lung cancer .</brief_summary>
	<brief_title>Photodynamic Therapy With HPPH Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine systemic normal tissue toxicity photodynamic therapy HPPH patient early stage centrally obstruct non-small cell lung cancer . - Determine , preliminarily , efficacy regimen patient . OUTLINE : This dose-escalation study HPPH . Patients receive HPPH IV 1 hour day 1 . Patients undergo laser light therapy via bronchoscopy day 3 . Cohorts 3-6 patient receive escalate dos HPPH maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow least 6 month . PROJECTED ACCRUAL : Approximately 15-17 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm microinvasive centrally obstruct nonsmall cell lung cancer Squamous cell carcinoma Adenocarcinoma Large cell carcinoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % OR ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin great 3.0 mg/dL Alkaline phosphatase great 3 time upper limit normal ( ULN ) SGOT great 3 time ULN PT great 1.5 time ULN Renal : Creatinine great 3.0 mg/dL Pulmonary : No severe chronic obstructive pulmonary disease would preclude study Other : Not pregnant Fertile patient must use effective contraception No contraindication bronchoscopy No porphyria No hypersensitivity porphyrin porphyrinlike compound PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy lung cancer allow Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Prior endocrine therapy lung cancer allow Radiotherapy : At least 4 week since prior radiotherapy No concurrent external beam radiotherapy Surgery : No concurrent surgery Other : Prior therapy lung cancer allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
</DOC>